Deka Biosciences is a clinical-stage biotechnology company developing a novel class of targeted immunocytokines called Diakines for oncology and inflammatory diseases. The company's lead assets, DK210 (EGFR) for solid tumors and DK410 (VEGFR2) for Crohn's disease, leverage a proprietary platform designed to combine two synergistic cytokines with a tissue-targeting system in a single molecule. This approach aims to enhance therapeutic efficacy while significantly reducing systemic toxicity and improving pharmacokinetic profiles compared to conventional cytokine therapies.

Deka has successfully de-risked its lead oncology asset, DK210 (EGFR), through Phase 1 clinical trials, demonstrating a favorable safety profile with minimal cytokine release syndrome (CRS) and no vascular leak syndrome (VLS), even at high doses. The platform has shown strong preclinical data supporting its mechanism of action, including enhanced T cell function, blocked Treg expansion, and improved synapse formation. The company has a convertible note open as an immediate funding vehicle in parallel to their equity financing activities, anticipating a larger Series C financing round of $55 million by early 2H 2025. We are seeking a $2 million note.